Skip to contentL
Ligand Pharmaceuticals Inc
L
LGNDLigand Pharmaceuticals Inc Q4 2021 · 10-K
Revenue$56.40M$56.40M−19.4% vs Q4 2020 Net Income-$5.42M-$5.42MN/M vs Q4 2020 EPS Diluted-$0.19-$0.19N/M vs Q4 2020 Operating Incomederived$37,691,000+64.8% The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ligand Pharmaceuticals Inc · CIK 886163 · Engraved from SEC EDGAR
Operating Cash Flowderived$27,642,000+5,047.5% Free Cash Flowderived$25,447,000N/M Margins · derivedOperating margin66.8%+34.2 pt vs Q4 2020
Net margin-9.6%−17.8 pt vs Q4 2020
ended Dec 31, 2021 · filed Feb 28, 2022 · 59 d after period end